Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and approval decisions for new drug applications by health authorities is an uncertain and evolving process and health authorities retain significant discretion at all stages of the regulatory review and approval decision process; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (v) patents may not issue from our patent applications our proprietary or partnered drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; (vi) the outcome of any existing or future intellectual property or other litigation related to our proprietary or partnered drug candidates; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 7, 2013. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Investor Inquiries: Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC 

(212)
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or ... Omega-3 therapies for cardiovascular disease and overall health is pleased ... in 2014 and its outlook for 2015 from the CEO, ... We would like to take this opportunity to ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Advocate Christ,Medical Center in Oak Lawn, Ill. has ... area, the only one in the Advocate Health Care ... a glue-like liquid for,the successful treatment of brain aneurysms ... J. Grobelny MD, of,the medical center,s Neurosciences Institute, led ...
... 19 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... (NYSE: WYE ), has exercised its option ... to extend the research period for an,additional one-year ... of the,research period extension, Wyeth,s obligations to Trubion ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:1/22/2015)... (PRWEB) January 23, 2015 LunaDress, with its ... the fashion industry. Now, the business is showing its latest ... women’s dresses. , According to the company’s CEO, all the ... now offered with big discounts, up to 80% off. All ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... WASHINGTON, Feb. 2 Danaher Corporation (NYSE: ... Financial Officer, Daniel L. Comas will be presenting at ... on Monday, February 9, 2009 at 1:35 p.m. EST. ... . A replay of the webcast will be available ...
... (Nasdaq: DRAD ), a leading provider of ... that improve patient care while driving positive healthcare economics, ... to three northern California service hub locations. The ... Office Solutions calls for the sale of portable nuclear ...
... be considered, AHA panel says , , MONDAY, Feb. 2 ... should be used cautiously to minimize patient exposure to ... That,s the conclusion of a new American Heart Association ... Circulation . , Sources of ionizing radiation include ...
... contradicting previous research , , MONDAY, Feb. 2 (HealthDay News) ... decline among the elderly, new research shows. , The ... lowered the risk for Alzheimer,s disease and dementia. , ... the number of years of schooling you,ve had," said ...
... Ohio, Feb. 2 The National Committee for Quality,Assurance ... as a New,Health Plan for its Medicaid program through ... , NCQA Accreditation is based ... get high-quality care. Accreditation evaluates not only the health,plan,s ...
... overestimate their actual risk of medical malpractice lawsuits, according to ... Public Health and Community Medicine in Seattle, WA. , ... one in 2006 that asked radiologists in diverse regions of ... malpractice claim related to mammography? And what do you think ...
Cached Medicine News:Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Experts Urge Limits on Use of Cardiac CT Scans 2Health News:Education Doesn't Slow Alzheimer's Decline 2Health News:Unison Health Plan of Ohio Accredited by NCQA 2
... cutting speeds (guillotine movements) are possible. Cutting ... off, thus minimizing tissue trauma. One can ... both can be combined together. There are ... bi-manual techniques. Lightweight autoclavable hand-pieces with single ...
A wide selection of bipolar forceps and hemostatic erasers to facilitate most ophthalmic surgical procedures....
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: